EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Current status of white coat hypertension: where are we?

Gani Nuredini iD, Alec Saunders iD, Chakravarthi Rajkumar, Michael Okorie iD

Therapeutic Advances in Cardiovascular Disease · 2020-01 · 14

DOI: 10.1177/1753944720931637 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 24.06.2020. Verfasst von Gani Nuredini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Brighton and Sussex Medical School, Brighton, UK. Hauptthemen laut MEDLINE: Blood Pressure. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

White coat hypertension (WCH) is characterised by an elevated clinic blood pressure (BP) with normal ambulatory or home BP. It is well recognised in clinical practice and occurs in approximately one-third of untreated patients with elevated clinic BP. Current evidence suggests that WCH is associated with cardiovascular risk factors, including the development of sustained hypertension and the presence of target organ damage. However, its effects on cardiovascular outcomes remain a matter of debate. There is also insufficient evidence from randomised controlled trials to determine whether WCH warrants treatment. This narrative review aims to provide an update on the current understanding of WCH. It focuses on the clinical characteristics and potential implications of WCH, its relationship to cardiovascular risk and the evidence regarding treatment. Gaps in existing research are also highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureAntihypertensive AgentsBlood Pressure DeterminationDisease ProgressionHumansOffice VisitsPhenotypeRisk FactorsTreatment OutcomeWhite Coat Hypertension

Stichwörter der Autor:innen

cardiovascular risktarget organ damagewhite coat hypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Medicine, Brighton and Sussex Medical School, Brighton, UK.
  • Division of Medicine, Brighton and Sussex University Hospitals, Brighton, UK.
  • Department of Medicine, Brighton and Sussex Medical School, Watson Building (Room 344), Falmer, Brighton, BN1 9PH, UK.

ORCID-Profile: Gani Nuredini, Alec Saunders, Michael Okorie

Zitieren

APA

Nuredini, G., Saunders, A., Rajkumar, C., & Okorie, M. (2020). Current status of white coat hypertension: where are we?. Therapeutic Advances in Cardiovascular Disease, 14. https://doi.org/10.1177/1753944720931637

Vancouver

Nuredini G, Saunders A, Rajkumar C, Okorie M. Current status of white coat hypertension: where are we?. Therapeutic Advances in Cardiovascular Disease. 2020;14. doi:10.1177/1753944720931637

BibTeX
@article{Nuredini2020,
  author = {Nuredini, Gani and Saunders, Alec and Rajkumar, Chakravarthi and Okorie, Michael},
  title = {Current status of white coat hypertension: where are we?},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2020},
  volume = {14},
  doi = {10.1177/1753944720931637}
}
Kostenlos starten →